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Mitochondrial Respiration Is Decreased in Skeletal
Muscle of Patients With Type 2 Diabetes
Martin Mogensen,1 Kent Sahlin,1,2,3 Maria Fernstro¨m,2,3 Dorte Glintborg,4 Birgitte F. Vind,4
Henning Beck-Nielsen,4 and Kurt Højlund4
We tested the hypothesis of a lower respiratory capacity
per mitochondrion in skeletal muscle of type 2 diabetic
patients compared with obese subjects. Muscle biopsies
obtained from 10 obese type 2 diabetic and 8 obese nondi-
abetic male subjects were used for assessment of 3-
hydroxy-Acyl-CoA-dehydrogenase (HAD) and citrate synthase
activity, uncoupling protein (UCP)3 content, oxidative
stress measured as 4-hydroxy-2-nonenal (HNE), fiber type
distribution, and respiration in isolated mitochondria. Res-
piration was normalized to citrate synthase activity (mito-
chondrial content) in isolated mitochondria. Maximal ADP-
stimulated respiration (state 3) with pyruvate plus malate
and respiration through the electron transport chain
(ETC) were reduced in type 2 diabetic patients, and the
proportion of type 2X fibers were higher in type 2 diabetic
patients compared with obese subjects (all P < 0.05).
There were no differences in respiration with palmitoyl-L-
carnitine plus malate, citrate synthase activity, HAD activ-
ity, UCP3 content, or oxidative stress measured as HNE
between the groups. In the whole group, state 3 respiration
with pyruvate plus malate and respiration through ETC
were negatively associated with A1C, and the proportion of
type 2X fibers correlated with markers of insulin resis-
tance (P < 0.05). In conclusion, we provide evidence for a
functional impairment in mitochondrial respiration and
increased amount of type 2X fibers in muscle of type 2
diabetic patients. These alterations may contribute to the
development of type 2 diabetes in humans with obesity.
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Type 2 diabetes is characterized by insulin resis-tance in major metabolic tissues such as skeletalmuscle, liver, and adipose tissue, as well asfailure of the pancreatic -cells to compensate
for this abnormality (1). Skeletal muscle is the major site
of glucose disposal in response to insulin and, correspond-
ingly, the major site of insulin resistance in type 2 diabetes
(1,2). Despite extensive research, the mechanisms under-
lying insulin resistance are not fully understood. Indeed,
several abnormalities have been identified in insulin-
resistant muscle including impaired insulin activation of
glycogen synthase (1,3), impairment of the proximal com-
ponents of the insulin signaling cascade (2), and increased
intramuscular triglyceride content (4,5). Another impor-
tant component of insulin resistance appears to be a
decreased ability of insulin to regulate fuel utilization
(6–8). In insulin-resistant subjects, this impaired ability to
switch from lipid to carbohydrate oxidation in response to
insulin has been described as “metabolic inflexibility” of
skeletal muscle (8).
Being the site of fuel oxidation, the mitochondrion has
gained increasing interest in type 2 diabetes research
during the last decade. Several studies have indicated a
role for mitochondrial dysfunction in the pathogenesis of
insulin resistance and type 2 diabetes. This includes re-
ports of a decreased leg lipid oxidation in type 2 diabetes
and obesity (9) and a strong negative correlation between
leg lipid oxidation and insulin resistance (10–13). Further-
more, microarray analysis has revealed a coordinated
downregulation of genes involved in mitochondrial oxida-
tive phosphorylation in type 2 diabetic patients and high-
risk individuals (14–16), and proteomic analysis has
demonstrated a decreased content of the ATP synthase
-subunit in type 2 diabetic patients (17). These findings
are supported by reports of a decreased activity of the
electron transport chain (ETC) in muscle mitochondria in
type 2 diabetes and obesity (18,19) and in vivo studies
using magnetic resonance spectroscopy showing impaired
mitochondrial ATP production in insulin-resistant off-
spring of type 2 diabetic patients (20).
Nevertheless, it remains to be fully clarified whether
mitochondrial dysfunction in type 2 diabetes and obesity is
caused by a reduced content of mitochondria, a reduced
functional capacity, or a combination of both. In a study by
Kelley et al. (18), it was reported that the ratio between the
activities of NADH:O2 oxidoreductase and citrate synthase
(a marker of mitochondria content) in skeletal muscle did
not differ between lean and obese nondiabetic subjects
and type 2 diabetic patients. In a more recent study from
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the same research group, ETC activity was measured as
the activity of succinate oxidase in the subsarcolemmal
and intermyofibrillar subpopulations of muscle mitochon-
dria (19). Total ETC activity corrected for mitochondrial
content (mitochondrial DNA) was reduced in both type 2
diabetes and obesity compared with lean subjects. More-
over, ETC activity in the subsarcolemmal mitochondria
fractions was reduced in type 2 diabetic patients com-
pared with obese subjects, but this was not corrected for
mitochondrial content (19). Thus, it is still unclear
whether the respiratory capacity per mitochondrion is
reduced in type 2 diabetic patients compared with obese
nondiabetic subjects.
An essential feature of the mitochondrion is the cou-
pling between substrate oxidation and phosphorylation of
ADP through generation and utilization of the proton
gradient over the inner mitochondrial membrane. Previous
studies have suggested a possible link between insulin
resistance and the coupling of these systems (21). The
functionality of the mitochondrion can be assessed by
measuring respiration in isolated mitochondria from hu-
man skeletal muscle under controlled conditions without
the influence of circulating hormones and substrates (22).
Here, the intactness of the inner membrane is sustained,
enabling an interaction between substrate oxidation and
phosphorylation. By using different substrate combina-
tions, different enzymatic pathways can be included and
excluded. The mitochondrial respiratory rate will thereby
describe the functionality and interaction between these
pathways. By relating the mitochondrial respiration to
citrate synthase activity, the respiratory capacity per mi-
tochondrion can be assessed. To our knowledge, no
previous studies have investigated the respiratory function
of the mitochondrion in skeletal muscle of type 2 diabetic
patients.
The present study was undertaken to investigate the
role of mitochondrial dysfunction in insulin resistance in
skeletal muscle of patients with type 2 diabetes. To
account for the effects of fiber type composition, mito-
chondrial content, obesity, and oxidative stress induced by
hyperglycemia, we measured the respiratory capacity per
mitochondrion, oxidative stress as 4-hydroxy-2-nonenal
(HNE), and fiber type distribution in skeletal muscle of
type 2 diabetic patients and well-matched obese, healthy
subjects.
RESEARCH DESIGN AND METHODS
Ten patients with type 2 diabetes and eight healthy control male subjects,
matched according to age and BMI, participated in the study (Table 1). All
subjects were obese and sedentary and did not participate in any kind of
physical training. Type 2 diabetic patients were treated with either diet alone
or diet in combination with sulfonylurea, metformin, or insulin. Medication
was withdrawn 1 week before the study. The patients were all GAD65
antibody negative and without signs of diabetic retinopathy, neuropathy,
nephropathy, or macrovascular complications. The control subjects had
normal glucose tolerance and no family history of diabetes. All subjects had
normal results on screening blood tests of hepatic and renal function. All
subjects gave written informed consent, and the study was approved by the
local ethics committee of Funen and Vejle County and was performed in
accordance with the Declaration of Helsinki. Participants were instructed to
avoid vigorous exercise for 48 h before the study, which was carried out after
a 10-h overnight fast. Fasting blood samples were analyzed for glucose
(Glucose Analyzer II; Beckman Instruments, Fullerton, CA), A1C, free fatty
acids (FFAs) (Wako Chemicals, Neuss, Germany), triglycerides, total choles-
terol, insulin, and C-peptide (Wallac, Turku, Finland). Homeostasis model
assessment of insulin resistance (HOMA-IR) was calculated from fasting
values of serum insulin and plasma glucose (23).
Muscle biopsies and preparation of mitochondria. Muscle biopsies were
taken from the vastus lateralis muscle using a modified Bergstro¨m needle with
suction under local anesthesia (5 ml lidocaine 2%). A small part of the biopsy
(50–100 mg) was rapidly frozen in liquid nitrogen and stored at 80°C for
later determination of oxidative enzyme activities, uncoupling protein (UCP)3
protein content, fiber type distribution, and oxidative stress (HNE). The major
part (100–150 mg) of the biopsy was used for isolation of mitochondria as
previously described (24). Using this method, both the subsarcolemmal and
intramyofibrillar mitochondrial fractions are isolated. Due to transportation
(from Odense University Hospital to University of Southern Denmark,
Odense, Denmark), muscle samples were on average stored for 45 min (all1
h) in ice-cold isolation buffer before initiation of the isolation procedure. The
major part of the isolated mitochondria was used for assessment of respira-
tory function. The remaining part was frozen in liquid nitrogen and stored at
80°C for later assessment of citrate synthase activity and maximal respira-
tion through ETC.
Mitochondrial respiratory activity. Mitochondrial oxygen consumption
was measured polarographically using a Clark-type electrode (DW1 oxygraph;
Hansatech Instruments, Norfolk, U.K.). The electrode was surrounded by a
temperature-controlled water-jacketed glass chamber maintaining the temper-
ature at 25°C. The oxygraph was equipped with magnetic stirring and a
gas-tight plunger ensuring a minimum of oxygen diffusion between the
chamber solution and the surroundings. For data collection, the electrode was
connected to a computer. The measurement was carried out in an oxygraph
medium containing 225 mmol/l mannitol, 75 mmol/l sucrose, 10 mmol/l Tris, 10
mmol/l KCl, 10 mmol/l K2HPO4, 0.1 mmol/l EDTA, 0.8 mmol/l MgCl2(6H2O),
and pH 7.0. A total of 5 mmol/l pyruvate  2 mmol/l L-malate and 10 mol/l
palmitoyl-L-carnitine 2 mmol/l L-malate was used as substrate combinations.
Mitochondrial respiration was initiated by the addition of mitochondrial-rich
suspension medium. After reaching a stable rate, maximal respiration was
initiated by adding K-ADP (final concentration 0.3 mmol/l). After determina-
tion of the maximal ADP-initiated respiration (termed Vmax or state 3) and
respiration without ADP (termed noncoupled respiration or state 4), the
oxygen tension was regained and the submaximal respiration initiated by
low-rate ADP infusion. This was accomplished by the use of a microdialysis
pump (CMA/102; CMA/Microdialysis, Solna, Sweden) with a pumping rate
ranging from 0.1 to 20 l/min. At 50% of state 3 respiration, a sample was
withdrawn from the respiratory chamber for calculation of ADP sensitivity
([ADP]1⁄2Vmax) as described previously (25).
Maximal respiration through ETC was determined in permeabilized mito-
chondria. Permeabilization was accomplished by addition of alamethicin to
the respiratory medium (final concentration 6 g/ml) (18). Maximal respira-
tion was determined in the presence of 2 mol/l cytochrome c and initiated by
addition of 450 mol/l NADH. The measurement of respiration through ETC in
mitochondria from one control subject was excluded from further analysis
due to signs of mitochondrial degeneration. This was confirmed by reevalua-
tion of citrate synthase activity, which was only 25% of the expected value in
the particular sample.
TABLE 1
Clinical, metabolic, and muscle characteristics
Type 2 diabetic
subjects
Control
subjects P
Age (years) 55 2 53  2 0.36
BMI (kg/m2) 31  1 32  1 0.77
Weight (kg) 99 4 106  6 0.36
Plasma glucose (mmol/l) 11.5 1.6 5.8 0.1 0.006
A1C (%) 7.4 0.4 5.5 0.1 0.001
C-peptide (pmol/l) 1312 167 929 97 0.08
Insulin (pmol/l) 100 24 76 12 0.41
FFA (mmol/l) 0.6 0.1 0.6 0.1 0.73
Total cholesterol (mmol/l) 5.7 0.3 5.4 0.3 0.60
Triglyceride (mmol/l) 1.4 0.2 2.9 1.1 0.28
HOMA-IR 8.0 1.7 3.3 0.51 0.03
Citrate synthase activity 104 8 110 11 0.63
HAD activity 160 13 161 11 0.95
UCP3 1.4 0.2 1.2 0.3 0.69
UCP3 per mitochondrion 1.3 0.2 1.1 0.2 0.44
Data are means  SE from 10 type 2 diabetic patients and 8 obese
control subjects. Citrate synthase and HAD activity was measured as
units  mg protein1  min1. UCP3 was determined as arbitrary units
per miligram protein. UCP3 per mitochondrion was determined as
arbitrary units/103 per citrate synthase activity.
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All respiratory measurements were related to citrate synthase activity in
mitochondrial suspension (26). Respiratory control index (RCI  state 3/state
4), P/O ratio (mitochondrial efficiency), and P/O ratio during submaximal
respiration (33% of state 3) were calculated. RCI describes the coupled state
of the mitochondrion, and P/O ratio describes the efficiency of the mitochon-
drion, calculated as the amount of ADP consumed per oxygen being reduced.
Both values were used to evaluate the success of the isolation procedure and
the proton leak across the inner membrane. The P/O ratio at submaximal
respiration was calculated to evaluate the mitochondrial efficiency, while
sustaining a membrane potential (27).
Enzyme activity, fiber type distribution, and UCP3 content. The activity
of 3-hydroxy-Acyl-CoA-dehydrogenase (HAD) and citrate synthase was spec-
trophotometrically determined at 25°C as described (28,29). Citrate synthase
and HAD activity was determined as unit per miligram muscle protein per
minute (BCA Protein Assay Kit; Pierce, Rockford, IL). Fiber type distribution
was determined by electrophoresis as different isotypes of myosin heavy chain
(type 1 fibers, type 2A fibers, and type 2X fibers) as previously described (30).
Determination of percentage of type 1 fibers by either this method or the
histochemical method correlates significantly (r  0.96) (31). Determination
of UCP3 content was analyzed in duplicate as previously described in detail
(32).
Oxidative stress. HNE is a major product of endogenous lipid peroxidation
that reacts with several functional groups in muscle proteins to form
thioesters and Michael adducts. Protein modification by HNE was performed
by immunoblotting as described (33). Freeze-dried muscle samples were
homogenized for 5 min in cold lysing buffer in 1:70 wt/vol, extracted for 15 min
at 4°C with slow mixing, and centrifuged at 1,000g for 10 min. Protein
concentration of the supernatant was determined with a protein assay kit
(BCA Pierce). Equal amounts of proteins (15 g) were loaded and separated
on SDS-PAGE (BioRad) and transferred to polyvinylidene difluouride mem-
branes. After blocking in Tris-buffered saline with 5% nonfat milk, the
membranes were incubated with primary polyclonal antibodies to the HNE
adducts (Alpha Diagnostics), followed by incubation with horseradish peroxi-
dise–conjugated secondary antibody (anti-goat; Santa Cruz Bio Technology).
The membrane was incubated with chemiluminescence detection reagent
enhanced chemiluminescence (Amersham). Actin protein content was deter-
mined with primary antibodies to actin (anti-rabbit; Sigma) on the same
membrane after stripping the membrane in stripping buffer (Pierce). Quanti-
fication was performed with Quantity One 1-D Analyzing software (Bio-Rad).
Statistics. Data are presented as means  SE. Differences between type 2
diabetic and control subjects were tested for statistical significance with the
Student’s unpaired t test. Correlation between variables was tested with
Pearson correlation analysis. Statistical significance was accepted at P 0.05.
RESULTS
Clinical, metabolic, and muscle characteristics. Type
2 diabetic patients had significantly higher concentrations
of fasting plasma glucose and A1C compared with obese
subjects (Table 1). There were no differences between
groups in the circulating concentrations of C-peptide,
insulin, FFA, total cholesterol, or triglycerides. Insulin
resistance determined as HOMA-IR was significantly
higher in diabetic patients compared with obese subjects.
Analyses of citrate synthase and HAD activity revealed
no significant differences between type 2 diabetic patients
and obese subjects (Table 1). Type 2 diabetic patients had
a significant higher proportion of type 2X fibers, but no
differences in type 1 or type 2A fibers were found between
the groups (Fig. 1A). Furthermore, there were no differ-
ences in muscle oxidative stress measured as HNE (Fig.
1B) or in UCP3 content measured per miligram protein or
per mitochondrion (citrate synthase activity) between the
groups.
Mitochondrial characteristics. Maximal respiration
through ETC was significantly reduced in type 2 diabetic
patients compared with obese subjects (Fig. 2A). Maximal
ADP-stimulated respiration (state 3) with pyruvate plus
malate was also significantly reduced in type 2 diabetic
patients compared with obese subjects, whereas state 3
respiration with palmitoyl-L-carnitine plus malate did not
differ between the groups (Fig. 2B and C). In type 2
diabetic patients, RCI was significantly lower than in
obese subjects but, again, only when using pyruvate plus
malate as substrates (Table 2). Type 2 diabetic patients
had a slightly lower P/O ratio using pyruvate plus malate,
but this did not reach statistical significance. There were
no significant differences in the P/O ratio during submaxi-
mal respiration or ADP sensitivity between the groups
regardless of which substrates were used.
Correlation analysis. To explore potential mechanisms
underlying reduced state 3 respiration and respiration
through ETC, we examined the relationship between these
measures of mitochondrial respiration and muscle and
metabolic characteristics. In the whole study group (n 
18), state 3 respiration with pyruvate plus malate corre-
lated negatively with A1C (r  0.51, P  0.03) (Fig. 3A)
and tended to correlate with plasma glucose (r  0.46,
P  0.052). Respiration through ETC was also inversely
correlated with A1C (r0.49, P 0.048) (Fig. 3B). State
3 respiration with palmitoyl-L-carnitine plus malate was
positively correlated with the proportion of type 1 fibers
FIG. 1. Fiber type distribution and oxidative stress in human skeletal
muscle from obese patients with type 2 diabetes (T2D) and obese
control subjects. A: Proportions (%) of type 1, type 2A, and type 2X
fibers in skeletal muscle from 10 diabetic (f) and 8 control ()
subjects. Data are means SE. B: Oxidative stress measured as HNE in
skeletal muscle of 10 diabetic (F) and 8 control (E) subjects. The mean
value for each group is indicated by a line. *P < 0.05 vs. control
subjects.
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(r  0.50, P  0.04) and tended to correlate with A1C (r 
0.46, P  0.06). Neither respiration through ETC nor
state 3 respiration correlated with the amount of type 2X
fibers or HNE (oxidative stress).
We also studied the relationship between the amount of
type 2X fibers and the other parameters measured. There
was a significant positive correlation between the propor-
tion of type 2X fibers and state 4 respiration using both
pyruvate plus malate (r  0.55, P  0.02) and palmitoyl-
L-carnitine plus malate (r  0.54, P  0.02) as substrates.
Moreover the amount of type 2X fibers correlated posi-
tively with plasma glucose (r  0.48, P  0.04), FFAs (r 
0.53, P  0.02), insulin (r  0.55, P  0.01), C-peptide (r 
0.66, P  0.003), and HOMA-IR (r  0.76, P  0.001) (Fig.
3C and D).
DISCUSSION
Several studies have implicated a role for mitochondrial
dysfunction in the pathogenesis of skeletal muscle in-
sulin resistance (6,7,14–20). However, evidence for a
difference in mitochondrial function between obese
nondiabetic subjects and type 2 diabetic patients under
basal conditions is scarce (19), and the extent to which
this is caused by a lower mitochondrial content or an
impaired functional capacity remains unknown. The most
important finding of the present study was a reduced
respiratory function per mitochondrion in skeletal muscle
of type 2 diabetic patients compared with obese nondia-
betic subjects. Moreover, in the whole study group, the
measures of mitochondrial respiration were negatively
associated with A1C. However, muscle oxidative stress
measured as HNE was similar in type 2 diabetic patients
and obese subjects, and no correlation between mitochon-
drial respiration and HNE content was observed. Interest-
ingly, type 2 diabetic patients also had a twofold higher
proportion of type 2X muscle fibers compared with obese
subjects. In the whole study group, type 2X fiber content
correlated with several markers of insulin resistance but
not with state 3 respiration or respiration through ETC.
These results provide evidence for a qualitative defect in
the functional capacity of muscle mitochondria in type 2
diabetic patients, which together with higher type 2X fiber
FIG. 2. Respiration in isolated mitochondria from human skeletal
muscle of obese patients with type 2 diabetes (T2D) and obese control
subjects. A: Maximal respiration through the ETC in permeabilized
isolated mitochondria using NADH and cytochrome c as substrates.
Data are from 10 diabetic (F) and 7 control (E) subjects. The mean
value for each group is indicated by a line. States 3 and 4 respiration in
isolated mitochondria with pyruvate plus malate (Pyr) (B) and palmi-
toyl-L-carnitine plus malate (Pal) (C) as substrate combinations. Data
represent means SE from 10 diabetic (f) and 8 control () subjects.
All measures of respiration were divided by citrate synthase activity (U
CS) in the mitochondrial suspension to correct for mitochondrial
content. *P < 0.05 vs. control subjects.
TABLE 2
Mitochondrial characteristics
Type 2 diabetic
subjects
Control
subjects P
Pyruvate  malate
RCI 11.5 1.0 14.4 0.8 0.04
P/O ratio 2.47 0.03 2.63 0.08 0.08
P/O ratiosubmax 2.24 0.02 2.25 0.04 0.92
	ADP
Vmax 29.7 5.7 29.6 8.0 0.99
Palmitoyl-l-carnitine 
malate
RCI 7.2 0.8 7.9  0.6 0.47
P/O ratio 2.30 0.03 2.35 0.03 0.32
P/O ratiosubmax 1.67 0.08 1.64 0.04 0.77
	ADP
Vmax 9.8  1.9 9.5  1.1 0.92
Data are means  SE from 10 type 2 diabetic patients and 8 obese
control subjects. RCI is state 3 divided by state 4 respiration. P/O ratio
is the amount of ADP used per oxygen atom during state 3 respiration.
P/O ratiosubmax is P/O ratio determined during submaximal respiration.
	ADP
1/2Vmax is the concentration of ADP needed to induce 50% of state
3 respiration, a measure of mitochondrial ADP sensitivity.
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content may play a role in the muscle metabolic changes
leading to type 2 diabetes in humans with obesity.
Nonhypothesis-driven approaches using DNA microar-
rays and proteomics have demonstrated a coordinated
downregulation of nuclear-encoded genes encoding pro-
teins of the respiratory complexes (I–V) (14–16) and a
decreased protein content and phosphorylation of the ATP
synthase -subunit in skeletal muscle of type 2 diabetic
patients (17). These studies have pointed to abnormalities
in the respiratory complexes I–V in the inner mitochon-
drial membrane. Correspondingly, ETC activity measured
as the activity of NADH:O2 oxidoreductase (18) or succi-
nate oxidase (19) has been reported to be decreased in
muscle mitochondria of type 2 diabetic patients and obese
subjects compared with lean subjects. Furthermore, the
activity of succinate oxidase was found to be 50% lower in
subsarcolemmal mitochondria in type 2 diabetic patients
compared with obese subjects. However, the NADH:O2
oxidoreductase activity corrected for mitochondrial con-
tent (citrate synthase activity) was not different between
lean subjects, obese nondiabetic subjects, and type 2
diabetic patients (18). Moreover, although succinate oxi-
dase activity related to mitochondrial DNA was reduced in
type 2 diabetic patients and obese subjects compared with
lean subjects, no difference in succinate oxidase activity
corrected for mitochondrial content was reported be-
tween obese subjects and type 2 diabetic patients in either
the total population or the subsarcolemmal population of
mitochondria (19).
We report a decreased respiratory function per mito-
chondrion in obese type 2 diabetic patients compared with
obese nondiabetic subjects. This was evident in fully
coupled isolated mitochondria using pyruvate plus malate
(state 3 respiration) as substrates and in permeabilized
uncoupled mitochondria using NADH plus cytochrome c
(maximal respiration through ETC) as substrates. A de-
creased respiration per mitochondrion suggests an intrin-
sic inhibition or damage to some or more of the involved
mitochondrial pathways. When using pyruvate plus malate
as substrates, the respiration in isolated mitochondria is a
result of a complex interplay between tricarboxylic acid
(TCA) cycle activity, ETC activity, utilization of the mem-
brane potential, ATP synthase functionality, and the activ-
ity of adenine nucleotide translocase. Which of these
factors are responsible for the reduced state 3 respiration
with pyruvate plus malate in type 2 diabetic patients
compared with control subjects cannot be determined
from the present data. However, the concomitant finding
of a significant lower respiration through ETC in type 2
diabetic patients cannot be explained by a defect in the
conversion of pyruvate to acetyl-CoA. Moreover, respira-
tion with pyruvate plus malate is not increased further by
addition of substrates having the potential to increase
NADH production, indicating that pyruvate dehydroge-
nase and TCA cycle activity are unlikely to be the limiting
factors. Together with the finding of similar citrate syn-
thase activity in the two groups, these results suggest the
possibility of a defect within the respiratory complexes
I–V in the inner mitochondrial membrane. The failure to
observe a significant difference in respiration with palmi-
FIG. 3. Correlation analysis in the whole study group (n 18). The levels of A1C were negatively associated with state 3 respiration with pyryvate
plus malate (nmol  min1  U CS1) (A) and respiration through the ETC (nmol  min1  U CS1) (B). The proportion of type 2X fibers was
positively associated with FFA levels (C) and HOMA-IR (D).
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toyl-L-carnitine plus malate between obese nondiabetic
and type 2 diabetic subjects could at least in part be
explained by a lower respiration with palmitoyl-L-carnitine
plus malate rather than with pyruvate plus malate in
isolated mitochondria. Thus, with the same variations in
these measurements, a larger sample size is probably
required to prove significance. In vivo, however, mitochon-
drial oxidative metabolism is challenged by a number of
substrates simultaneously, and, hence, a qualitative defect
within the respiratory complexes I–V could have a more
pronounced negative effect on respiration with lipids.
Since only men with manifest type 2 diabetes were in-
cluded, further studies are needed to determine the extent
to which these findings apply to female subjects with type
2 diabetes and whether they are potential early defects in
the pathogenesis of type 2 diabetes.
In the present study, A1C was negatively associated
with state 3 respiration and respiration through ETC in the
whole study group. This is in accordance with a previous
study showing a significant inverse relationship between
the content and phosphorylation of ATP synthase -sub-
unit and glucose levels (17). These results seem to support
the hypothesis of a relationship between prolonged eleva-
tion in glucose levels and mitochondrial dysfunction
caused by an increased production of reactive oxygen
species (ROS) and oxidative stress (34). Mitochondria are
the major source of ROS and oxidative stress (90%), and
also the primary target for oxidative damage, when ROS
production exceeds the capacity of the endogenous ROS
scavenging system (35). Accordingly, several protein sub-
units in the mitochondrial respiratory complexes (I–V) are
susceptible to oxidative damage (36). However, to our
knowledge, no previous studies have reported measure-
ments of oxidative stress in skeletal muscle of insulin-
resistant subjects. Surprisingly, we found no difference in
muscle oxidative stress measured as HNE between type 2
diabetic patients and obese subjects. Although we did not
measure other oxidative modifications such as nitration
and carbonylation or local oxidative damage within mito-
chondria, it is likely that these measures would parallel
those of HNE. Our data do not rule out a role for oxidative
stress in mitochondrial dysfunction in both obesity and
type 2 diabetes but indicate that the observed difference in
quality of mitochondrial respiration between type 2 dia-
betic patients and obese subjects is not mediated by
increased oxidative stress. It is therefore too early to
conclude that the observed negative association between
mitochondrial respiration and A1C is a causal relationship
involving increased ROS production.
Numerous factors are known to influence the mitochon-
drial function. Some of these factors, including age, obe-
sity, fiber type distribution, physical activity, and UCP3
protein, have also been related to insulin resistance and
type 2 diabetes. Physical activity has been shown to have
a positive influence on type 2 diabetes by increasing
insulin sensitivity and inducing weight loss. Muscular
adaptations in relation to increased physical fitness in-
clude an increased muscle oxidative capacity and in-
creased lipid oxidative capacity, mainly caused by an
increased mitochondrial volume (24). Therefore, it could
be argued that a potential lower level of physical activity in
type 2 diabetic patients contributed to the decrease in
mitochondrial respiration. However, previous studies have
shown a strong correlation between citrate synthase ac-
tivity and VO2max (37), and, in our study, citrate synthase
activity in type 2 diabetic patients and control subjects
was in fact similar. Furthermore, several studies have
shown that physical training does not affect measures of
respiration per mitochondrion when using pyruvate and
palmitoyl-L-carnitine plus malate as substrates (24,25,38).
Finally, the values of state 3 respiration with pyruvate plus
malate observed in the sedentary, obese, nondiabetic
subjects in the present study were similar to those previ-
ously reported in young healthy trained and untrained
subjects (38,39). For these reasons, we find it unlikely that
the decreased respiration per mitochondrion in type 2
diabetic patients was due to a potential minor difference in
physical activity.
In the present study, type 2 diabetic patients had a
twofold higher content of type 2X fibers. This is in
agreement with some (40,41), but not all, studies (42,43).
Furthermore, in accordance with earlier reports of a close
correlation between fiber type composition and insulin
sensitivity (41,44,45), we found that type 2X fiber content
was significantly associated with several markers of insu-
lin resistance including HOMA-IR and levels of FFAs.
Recent studies indicate that mitochondria from different
fiber types may have different metabolic characteristics.
This includes a higher UCP3 content in type 2X fibers in
human skeletal muscle (46) and a lower lipid oxidative
capacity per mitochondria and higher hydrogen peroxide
production in type 2 fibers from rodent muscle (27,47).
Correspondingly, we observed a positive association be-
tween the proportion of type 1 fibers and mitochondrial
respiration with palmitoyl-L-carnitine plus malate and a
correlation between type 2X fibers and noncoupled (state
4) respiration. In humans, muscle fiber type composition is
more mixed than in rodents, and generally type 2X fibers
have a very low oxidative capacity. Although there was no
relationship between mitochondrial respiration (state 3 or
through ETC) and the proportion of type 2X fibers, we
cannot rule out the possibility that decreased mitochon-
drial respiration in type 2 diabetic patients was in part
explained by an increased proportion of type 2X fibers
compared with obese subjects. On the other hand, single-
fiber analysis has demonstrated that reduced oxidative
capacity and increased lipid content in skeletal muscle of
type 2 diabetic patients are independent of the effect of
fiber type (42).
Previous studies have indicated that UCP3 may play an
essential role in mitochondrial dysfunction in type 2
diabetic patients (48). Despite extensive research, the
main function of UCP3 is still unknown. UCP3 has been
hypothesized to function as a protective mechanism
against ROS production by mild uncoupling of the inner
mitochondrial membrane and as a transporting protein of
nonesterified fatty acids from the matrix to the intermem-
brane space protecting the mitochondrion against peroxi-
dized lipids (49). At present, there is little evidence that
UCP3 functions as a fatty acid transporter. However, there
is some evidence supporting a role of UCP3 in the atten-
uation of mitochondrial ROS production (49). In the
present study, we found no difference in UCP3 protein
levels between type 2 diabetic patients and obese subjects.
This is in contrast to a recent study showing a decreased
UCP3 content in type 2 diabetic patients (50), probably
due to different matching of the study subjects with
respect to age, body composition, and physical activity.
Our findings strongly indicate that the decrease in respi-
ration per mitochondrion in type 2 diabetic patients com-
pared with obese subjects is not explained by changes in
UCP3 protein. On the other hand, even normal levels of
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UCP3 levels may contribute to mitochondrial damage in
type 2 diabetic patients in face of an increased oxidative
stress (34).
In summary, we provide evidence for a qualitative
defect in the respiratory function per mitochondrion in
skeletal muscle of type 2 diabetic patients compared with
obese nondiabetic subjects. This difference was not paral-
leled by increased oxidative stress in diabetic muscle.
Moreover, the proportion of type 2X fibers was higher in
type 2 diabetic patients and correlated with several mark-
ers of insulin resistance but not with mitochondrial respi-
ration. These alterations may be important factors
contributing to the progression from obesity to type 2
diabetes in humans. We were not able to demonstrate a
role for UCP3 levels, oxidative stress, or fiber type com-
position in the respiratory capacity of mitochondria, but a
significant negative correlation between mitochondrial
respiration and A1C indicates that elevated glucose levels
may contribute to mitochondrial dysfunction in obese and
type 2 diabetic subjects, perhaps by other mechanisms
than oxidative stress.
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